Somatostatin receptor subtype 2-mediated scintigraphy and localization using 99mTc-HYNIC-Tyr3-octreotide in human hepatocellular carcinoma-bearing nude mice

World Journal of Gastroenterology

Volumn 11, Issue 25, 2005, Pages 3953-3957

  Li, Yong ^a   Si, Jian Ming ^a   Zhang, Jun ^a   Du, Jin ^b   Wang, Fan ^b   Jia, Bing ^b  

^a ZHEJIANG UNIVERSITY   (China)

^b PEKING UNIVERSITY   (China)

Author keywords

99m Tc HYNIC Tyr3 octreotide; Hepatocellular carcinoma; Somatostatin receptor 2

Indexed keywords

HYDRAZINONICOTINIC ACID; MESSENGER RNA; NICOTINIC ACID DERIVATIVE; OCTREOTIDE[3 TYROSINE]; PENTOBARBITAL; RADIOISOTOPE; SOMATOSTATIN DERIVATIVE; SOMATOSTATIN RECEPTOR 2; TECHNETIUM 99M; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLADDER; CALCULATION; CANCER TISSUE; CANCER TRANSPLANTATION; CELL STRAIN HEPG2; CONTROLLED STUDY; DRUG BINDING; DRUG UPTAKE; HUMAN; HUMAN CELL; KIDNEY PARENCHYMA; KIDNEY TUBULE CELL; LIVER; LIVER CELL CARCINOMA; LIVER SCINTISCANNING; MEDICAL INSTRUMENTATION; MOUSE; MOUSE STRAIN; NONHUMAN; NUCLEAR MEDICINE; NUDE MOUSE; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS; TUMOR LOCALIZATION; URINARY EXCRETION;

EID: 22644432775     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v11.i25.3953     Document Type: Article

References (34)

1. Lamberts SW, de Herder WW, Hofland LJ. Somatostatin analogs in the diagnosis and treatment of cancer. Trends Endocrinol Metab 2002; 13: 451-456
2. Froidevaux S, Eberle AN. Somatostatin anlogs and radiopeptides in cancer therapy. Bioploymers 2002; 66: 161-183
3. Celinski SA, Fisher WE, Amaya F, Wu YQ, Yao Q, Youker KA, Li M. Somatostatin receptor gene transfer inhibits established panceatic cancer xenografts. J Surg Res 2003; 115: 41-47
4. Kumar M, Liu ZR, Thapa L, Wang DY, Tian R, Qin RY. Mechanisms of inhibition of growth of human pancreatic carcinoma implanted in nude mice by soamtostatin receptor subtype 2. Pancreas 2004; 29: 141-151
5. Pollak MN, Schally AV. Mechanisms of antineoplastic action of somatostatin analogs. Proc Soc Exp Biol Med 1998; 217: 143-152
6. Reubi JC, Kvols L, Krenning E, Lamberts SW. Distribution of somatostatin receptors in normal and tumor tissue. Metabolism 1990; 39(9 Suppl 2): 78-81
7. Lamberts SW, Krenning EP, Reubi JC. The role of somatostatin and its analogs in the diagnosis and treatment of tumors. Endocr Rev 1991; 12: 450-482
8. Lamberts SW, Van der Lely AJ, de Herder WW, Hofland LJ. Octreotide. N Engl J Med 1996; 334: 246-254
9. Weiner RE, Thakur ML. Radiolabeled peptide in the diagnosis and therapy of oncological diseases. Appl Radiat Isot 2002; 57: 749-763
10. Decristoforo C, Mather SJ. Technetium-99m somatostatin analogues: effect of labelling methods and peptide sequence. Eur J Nucl Med 1999; 26: 869-876
11. Towu E, Boxer G, Begent R, Zweit J, Spitz L, Hobbs K, Winslet M. In-vitro uptake of radioactive lipiodol I-131 and I-125 by hepatoblastoma: implications for targeted radiotherapy. Pediatr Surg Int 2001; 17: 609-613
12. Heppeler A, Froidevaux S, Eberle AN, Maecke HR. Receptor targeting for tumor localisation and therapy with radiopeptides. Curr Med Chem 2000; 7: 971-979
13. Hussain SA, Ferry DR, El-Gazzaz G, Mirza DF, James ND, McMaster P, Kerr DJ. Hepatocellular carcinoma. Ann Oncol 2001; 12: 161-172
14. Rougier P, Mitry E, Clavero-Fabri MC. Chemotherapy and medical treatment of hepatocellular carcinoma (HCC). Hepatogastroenterology 1998; 45(Suppl 3): 1264-1266
15. Perez CA, Brady LW. Principles and Practice of Radiation Oncology: Pancreatic and Hepatobiliary Cancer. Lippincott Company 1987: P810
16. Liu CL, Fan ST. Nonresectional therapies for hepatocellular carcinoma. Am J Sur 1997; 173: 358-365
17. 111In-labelled octreotide derivatives. Eur J Nucl Med 2000; 27: 1318-1325
18. 99mTc-EDDA/HYNIC-TOC). J Label Compd Radiopharm 2003; 46: 307-318
19. http://www.ncbi.nlm.nih.gov/blast
20. Krenning EP, de Jong M, Kooij PP, Breeman WA, Bakker WH, de Herder WW, van Eijk CH, Kwekkeboom DJ, Jamar F, Pauwels S, Valkema R. Radiolabelled somatostatin analogue (s) for peptide receptor scintigraphy and radionuclide therapy. Ann Oncol 1999; 10(Suppl 2): S23-29
21. Weckbecker G, Raule F, Stolz B, Bruns C. Somatostatin analogs for diagnosis and treatment of cancer. Pharmacol Ther 1993; 60: 245-264
22. 90Y-DOTA-D-Phel-Tyr3-octreotide. Eur J Nucl Med 2001; 28: 426-434
23. Reubi JC, Zimmermann A, Jonas S, Waser B, Neuhaus P, Laderach U, Wiedenmann B. Regulatory peptide receptors in human hepatocellular carcinomas. Gut 1999; 45: 766-774
24. Deng-Guo YAN, Qing-Jia OU. Somatostatin receptor subtype SSTR2 and SSTR3 mRNA expression in primary hepatic Carcinoma. Aizheng 2001; 20: 152-155
25. Hofland LJ, Lamberts SW. Somatostatin receptor subtype expression in human tumors. Ann Oncol 2001; 12(Suppl 2): S31-36
26. Rohrer L, Raulf F, Bruns C, Buettner R, Hofstaedter F, Schule R. Cloning and characterization of a fourth human somatostatin receptor. Proc Natl Acad Sci USA 1993; 90: 4196-4200
27. Kouroumalis E, Skordilis P, Termos K, Vasilaki A, Moschandrea J, Manousos ON. Treatment of hepatocellular carcinoma with octreotide: a randomized controlled study. Gut 1998; 42: 442-447
28. Holfland LJ, Lamberts SW. Somatostatin receptors and disease: Role of receptor subtypes. Bailliéres Clin Endocrinol Metab 1996; 10: 163-176
29. Patel YC. Somatostatin and its receptor family. Front Neuroendocrinol 1999; 20: 157-198
30. Reubi C, Horisberger U, Studer UE, Waser B, Laissue JA, Human kidney as target for somatostatin: high affinity receptors in tubules and vasa recta. J Clin Endocrinol Metab 1993; 77: 1323-1328
31. 1- octreotide. Bioconjug Chem 1998; 9: 192-200
32. Duncan JR, Stephenson MT, Wu HP, Anderson CJ. Indium-111-diethylenetriaminepentaacetic acid-octreotide is delivered in vivo to pancreatic, tumor cells, renal, and hepatocyte llysosomes. Cancer Res 1997; 57: 659-671
33. 1-octreotide in vivo. Bioconjug Chem 1998; 9: 662-670
34. 11In-DTPA- conjugated Peptides. Nucl Med Biol 2001; 28: 761-768